INNOVIVA, INC. (INVA) Gross Margin
- Gross margin · 12 months: Value 72.19%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 72.19% | Gross profit / revenue. Period ending 2026-06-30. $317.65M ÷ $440.00M × 100 ≈ 72.19% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 317.65M USD | Gross Profit |
| Revenue | 440.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $317.65M | $440.00M | (m) | 72.19% |
| 2026-03-31 | $310.19M | $420.69M | (m) | 73.73% |
| 2025-12-31 | $307.67M | $411.33M | (m) | 74.80% |
| 2025-09-30 | (m) | $388.52M | (m) | (m) |
| 2025-06-30 | (m) | $370.23M | (m) | (m) |
| 2025-03-31 | (m) | $369.84M | (m) | (m) |
| 2024-12-31 | (m) | $358.71M | (m) | (m) |
| 2024-09-30 | (m) | $352.75M | (m) | (m) |
| 2024-06-30 | (m) | $330.50M | (m) | (m) |
| 2024-03-31 | (m) | $311.59M | (m) | (m) |
| 2023-12-31 | (m) | $310.46M | (m) | (m) |
| 2023-09-30 | (m) | $290.43M | (m) | (m) |
| 2023-06-30 | (m) | $290.42M | (m) | (m) |
| 2023-03-31 | (m) | $317.65M | (m) | (m) |
| 2022-12-31 | (m) | $331.34M | (m) | (m) |
| 2022-09-30 | (m) | $373.22M | (m) | (m) |
| 2022-06-30 | (m) | $403.82M | (m) | (m) |
| 2022-03-31 | (m) | $396.41M | (m) | (m) |
| 2021-12-31 | (m) | $391.87M | (m) | (m) |
| 2021-09-30 | (m) | $374.66M | (m) | (m) |
| 2021-06-30 | (m) | $365.49M | (m) | (m) |
| 2021-03-31 | (m) | $343.63M | (m) | (m) |
| 2020-12-31 | (m) | $336.79M | (m) | (m) |
| 2020-09-30 | (m) | $322.29M | (m) | (m) |
| 2020-06-30 | (m) | $299.35M | (m) | (m) |
| 2020-03-31 | (m) | $284.51M | (m) | (m) |
| 2019-12-31 | (m) | $261.02M | (m) | (m) |
| 2019-09-30 | (m) | $264.90M | (m) | (m) |
| 2019-06-30 | (m) | $260.83M | (m) | (m) |
| 2019-03-31 | (m) | $263.81M | (m) | (m) |
| 2018-12-31 | (m) | $261.00M | (m) | (m) |
| 2018-09-30 | (m) | $250.67M | (m) | (m) |
| 2018-06-30 | (m) | $237.63M | (m) | (m) |
| 2018-03-31 | (m) | $229.10M | (m) | (m) |
| 2017-12-31 | (m) | $217.22M | (m) | (m) |
| 2017-09-30 | (m) | $191.31M | (m) | (m) |
| 2017-06-30 | (m) | $175.97M | (m) | (m) |
| 2017-03-31 | (m) | $149.88M | (m) | (m) |
| 2016-12-31 | (m) | $133.57M | (m) | (m) |
| 2016-09-30 | (m) | $112.79M | (m) | (m) |
| 2016-06-30 | (m) | $93.05M | (m) | (m) |
| 2016-03-31 | (m) | $71.23M | (m) | (m) |
| 2015-12-31 | (m) | $53.95M | (m) | (m) |
| 2015-09-30 | (m) | $38.39M | (m) | (m) |
| 2015-06-30 | (m) | $25.83M | (m) | (m) |
| 2015-03-31 | (m) | $16.11M | (m) | (m) |
| 2014-12-31 | (m) | $8.43M | (m) | (m) |
| 2014-09-30 | (m) | $2.85M | (m) | (m) |
| 2014-06-30 | (m) | $2.27M | (m) | (m) |
| 2014-03-31 | (m) | $3.58M | (m) | (m) |
| 2013-12-31 | (m) | $4.76M | (m) | (m) |
| 2013-09-30 | (m) | $8.86M | (m) | (m) |
| 2013-06-30 | (m) | $9.87M | (m) | (m) |
| 2013-03-31 | (m) | $10.00M | (m) | (m) |
| 2012-12-31 | (m) | $135.76M | (m) | (m) |
| 2012-09-30 | (m) | $135.32M | (m) | (m) |
| 2012-06-30 | (m) | $140.32M | (m) | (m) |
| 2012-03-31 | (m) | $145.28M | (m) | (m) |
| 2011-12-31 | (m) | $24.51M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $24.22M | (m) | (m) |
| 2009-12-31 | (m) | $24.37M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |